China's Shanghai Fosun wins race for India's Gland

Bayer Healthcare power ahead in China, Japan on Xarelto, Eylea

Today is the first day for England’s drug cost watchdog to take the reins of the beleaguered Cancer Drugs Fund and the moment it took over, NICE faced…

Vertex has pumped up the launch for slow-starting cystic fibrosis med Orkambi--but it took some serious spending to do it.

Sanofi finally won FDA approval of its long-awaited GLP-1 diabetes drug Adlyxin. But “finally” is the operative word, and the med will have to scramble with…

Bristol-Myers Squibb came through in Q2 on both the sales and earnings fronts and raised guidance once again. But it wasn’t Opdivo and the usual suspects…

It’s a silver-lining quarter for AstraZeneca. Second-quarter sales slid--but not as far as market watchers expected--and new cancer meds, diabetes drugs and…

China's Shanghai Fosun Pharmaceuticals has reportedly won a bidding war for India's privately held injectable maker Gland Pharma in a rare cross-…

As England's cost watchdogs were weighing Gilead’s evidence and pricing for its hep C drugs, the country’s National Health Service was maneuvering to…